Drug Approval | December 26, 2024
Aarti Drugs receives EIR from USFDA for Tarapur API facility
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Jagsonpal Pharmaceuticals has received full consideration of Rs. 41 crore towards the sale of the facility and will now be proceeding with registration formalities
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Akums Drugs will undertake this development and commercialization in India
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
The grant is designated for the research and development of Pyronaridine
Subscribe To Our Newsletter & Stay Updated
